IGN-2098 是一种口服有效的竞争性组胺 H2 受体 (H2 receptor) 拮抗剂,pA2 值为 7.32,可抑制基础及刺激状态下的胃酸分泌,加速溃疡愈合、抑制溃疡边缘隆起,并保护胃及十二指肠黏膜免受损伤,因此可用于胃溃疡的相关研究。
产品编号: MS-J73951 CAS No.: 126869-04-3 分子式: C22H32Cl2N4O2 分子量: 455.42
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

IGN-2098 是一种口服有效的竞争性组胺 H2 受体 (H2 receptor) 拮抗剂,pA2 值为 7.32,可抑制基础及刺激状态下的胃酸分泌,加速溃疡愈合、抑制溃疡边缘隆起,并保护胃及十二指肠黏膜免受损伤,因此可用于胃溃疡的相关研究。

生物实验数据

生物活性 IGN-2098 is an orally active, competitive histamine H2 receptor antagonist with a pA2 value of 7.32 that inhibits basal and stimulated gastric acid secretion, accelerates ulcer healing, suppresses elevation of the ulcer margin, and protects the gastric and duodenal mucosa from injury, and can therefore be used in research related to gastric ulcers.
IC50 & Target

H2 Receptor

7.32 (pA2)

体外研究
(In Vitro)

IGN-2098 可竞争性拮抗离体豚鼠心房标本中的组胺 H2 受体,其 pA2 值为 7.32。

体内研究
(In Vivo)

IGN-2098 (10-30 mg/kg;口服;每日 2 次;连续 14 天) 可剂量依赖性地促进大鼠乙酸诱导胃溃疡的愈合,其中 10 mg/kg 和 30 mg/kg 剂量的愈合率分别达到 49.6%和 52.7%,且与对照组相比能显著降低溃疡边缘隆起程度。
IGN-2098 (1-60 mg/kg;口服、皮下注射、皮内注射、腹腔注射;单次给药) 可通过多种途径强效抑制幽门结扎大鼠的基础胃酸分泌,其中皮下注射的效力最高 (胃酸分泌抑制的 ED50 = 0.7 mg/kg)。
IGN-2098 (0.1-30 mg/kg; 皮下注射; 单次给药) 可强效抑制急性瘘管大鼠中组胺刺激的胃酸分泌,其 ED50 为 0.2 mg/kg。
IGN-2098 (0.3-30 mg/kg;皮下注射;单次给药) 可强效抑制急性瘘管大鼠中 Carbachol (MS-U27390) 刺激的胃酸分泌,其 ED50 为 0.3 mg/kg。
IGN-2098 (1-30 mg/kg;皮下注射;单次给药) 可强效抑制急性瘘管大鼠中 Pentagastrin (MS-H98907) 刺激的胃酸分泌,其 ED50 为 0.1 mg/kg。
IGN-2098 (3-60 mg/kg;皮下注射;单次给药) 可抑制麻醉大鼠中 2-deoxy-D-glucose (MS-N96486) 刺激的胃酸分泌,其 ED50 为 42.7 mg/kg。
IGN-2098 (3-60 mg/kg;口服、皮下注射;单次给药) 可抑制大鼠幽门结扎诱导的胃溃疡,其 ED50 为 29.7 mg/kg。
IGN-2098 (1-60 mg/kg;口服;单次给药) 可抑制大鼠水浸应激诱导的胃黏膜损伤,其 ED50 为 8.4 mg/kg。
IGN-2098 (0.3-3 mg/kg;口服;单次给药) 可强效抑制组胺诱导的大鼠胃黏膜损伤,其 ED50 为 0.9 mg/kg。
IGN-2098 (3-30 mg/kg;口服;单次给药) 可抑制 Indomethacin (MS-W76510) 诱导的大鼠胃黏膜损伤,其 ED50 为 5.4 mg/kg。
IGN-2098 (1-30 mg/kg;口服;单次给药) 可强效抑制大鼠体内盐酸-Aspirin (MS-D43752) 诱导的胃黏膜损伤,其 ED50 为 1.4 mg/kg。
IGN-2098 (3-60 mg/kg;口服;单次给药) 可抑制大鼠由盐酸-乙醇诱导的胃黏膜损伤,其 ED50 为 17.0 mg/kg。

Animal Model: Sprague-Dawley (male, 7 weeks old, gastric ulcer induced by 20% acetic acid injection)
Dosage: 10 mg/kg; 30 mg/kg
Administration: p.o.; twice daily; 14 days
Result: Reduced mean ulcer index to 6.4 mm2 and achieved a 49.6% healing ratio at 10 mg/kg, with a significant difference versus control.
Reduced mean ulcer index to 6.0 mm2 and achieved a 52.7% healing ratio at 30 mg/kg, with a significant difference versus control.
Significantly reduced prominent ulcer edges versus control at both 10 mg/kg and 30 mg/kg.
Animal Model: Sprague-Dawley (male, SPF, 220-270g)
Dosage: 1-60 mg/kg (p.o.); 0.3-30 mg/kg (s.c.); 1-30 mg/kg (i.d.); 1-30 mg/kg (i.p.)
Administration: p.o.; single dose (0.5, 3, or 9 hours before pylorus ligation); s.c.; single dose (0.5 hours before pylorus ligation); i.d.; single dose (immediately after pylorus ligation); i.p.; single dose (0.5 hours before pylorus ligation)
Result: Reduced gastric juice volume by 53.1% and acid output by 78.5% at 10 mg/kg p.o.
0.5 hours before ligation, with an ED50 of 4.3 mg/kg for acid output inhibition.
Reduced acid output by 71.7% at 10 mg/kg p.o.
3 hours before ligation, and by 88.0% at 30 mg/kg p.o.
3 hours before ligation, with an ED50 of 5.0 mg/kg.
Reduced acid output by 66.5% at 30 mg/kg p.o.
9 hours before ligation, and by 78.8% at 60 mg/kg p.o.
9 hours before ligation, with an ED50 of 16.9 mg/kg.
Reduced acid output by 71.2% at 1 mg/kg s.c., with an ED50 of 0.7 mg/kg.
Reduced acid output by 65.0% at 3 mg/kg i.d., with an ED50 of 1.1 mg/kg.
Reduced acid output by 64.5% at 10 mg/kg i.p., with an ED50 of 3.6 mg/kg.
Animal Model: Sprague-Dawley (male, SPF, 220-270g)
Dosage: 0.1-30 mg/kg
Administration: s.c.; single dose (0.5 hours before first histamine administration)
Result: Reduced histamine-stimulated acid output by 30.3% at 0.1 mg/kg, 69.3% at 0.3 mg/kg, 73.5% at 1 mg/kg, 89.4% at 3 mg/kg, 92.0% at 10 mg/kg, and 97.5% at 30 mg/kg.
Achieved an ED50 of 0.2 mg/kg for acid output inhibition.
Animal Model: Sprague-Dawley (male, SPF, 220-270g)
Dosage: 0.3-30 mg/kg
Administration: s.c.; single dose (0.5 hours before carbachol infusion)
Result: Reduced carbachol-stimulated acid output by 42.9% at 0.3 mg/kg, 65.5% at 1 mg/kg, 78.1% at 3 mg/kg, 85.6% at 10 mg/kg, and 80.8% at 30 mg/kg.
Achieved an ED50 of 0.3 mg/kg for acid output inhibition.
Animal Model: Sprague-Dawley (male, SPF, 220-270g)
Dosage: 1-30 mg/kg
Administration: s.c.; single dose (0.5 hours before pentagastrin infusion)
Result: Reduced pentagastrin-stimulated acid output by 79.5% at 1 mg/kg, 52.7% at 3 mg/kg, 84.9% at 10 mg/kg, and 98.3% at 30 mg/kg.
Achieved an ED50 of 0.1 mg/kg for acid output inhibition.
Animal Model: Sprague-Dawley (male, SPF, 220-270g)
Dosage: 3-60 mg/kg
Administration: s.c.; single dose (0.5 hours after stimulated secretion stabilized)
Result: Reduced 2-deoxy-D-glucose-stimulated acid output by 65.9% at 60 mg/kg.
Achieved an ED50 of 42.7 mg/kg for acid output inhibition.
Animal Model: Sprague-Dawley (male, SPF, 220-270g)
Dosage: 3-60 mg/kg
Administration: p.o.; single dose (30 minutes before ligation); s.c.; single dose (7 hours after ligation)
Result: Reduced ulcer coefficients by 55.9% at 30 mg/kg, and 61.8% at 60 mg/kg.
Achieved an ED50 of 29.7 mg/kg for ulcer inhibition.
Animal Model: Sprague-Dawley (male, SPF, 220-270g)
Dosage: 1-60 mg/kg
Administration: p.o.; single dose (30 minutes before stress exposure)
Result: Reduced lesion length by 43.1% at 3 mg/kg, 59.1% at 10 mg/kg, 55.8% at 30 mg/kg, and 84.0% at 60 mg/kg.
Achieved an ED50 of 8.4 mg/kg for lesion inhibition.
Animal Model: Sprague-Dawley (male, SPF, 220-270g)
Dosage: 0.3-3 mg/kg
Administration: p.o.; single dose (30 minutes before histamine administration)
Result: Reduced lesion area by 86.7% at 3 mg/kg.
Achieved an ED50 of 0.9 mg/kg for lesion inhibition.
Animal Model: Sprague-Dawley (male, SPF, 220-270g)
Dosage: 3-30 mg/kg
Administration: p.o.; single dose (30 minutes before indomethacin administration)
Result: Reduced lesion length by 52.2% at 10 mg/kg, and 91.8% at 30 mg/kg.
Achieved an ED50 of 5.4 mg/kg for lesion inhibition.
Animal Model: Sprague-Dawley (male, SPF, 220-270g)
Dosage: 1-30 mg/kg
Administration: p.o.; single dose (30 minutes before HCl-aspirin administration)
Result: Reduced lesion length by 78.1% at 3 mg/kg, 90.9% at 10 mg/kg, and 95.0% at 30 mg/kg.
Achieved an ED50 of 1.4 mg/kg for lesion inhibition.
Animal Model: Sprague-Dawley (male, SPF, 220-270g)
Dosage: 3-60 mg/kg
Administration: p.o.; single dose (30 minutes before HCl-ethanol administration)
Result: Reduced lesion length by 62.0% at 20 mg/kg, 77.3% at 30 mg/kg, and 94.1% at 60 mg/kg.
Achieved an ED50 of 17.0 mg/kg for lesion inhibition.

化学信息

分子量 455.42
分子式 C22H32Cl2N4O2
CAS No. 126869-04-3

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础